[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@DraMartinezLago Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1053897615295856640.png) @DraMartinezLago Nieves Martinez Lago MD PhD

Nieves Martinez Lago MD PhD posts on X about promising, matterhorn, combo, cest the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

### Engagements: XXXXX [#](/creator/twitter::1053897615295856640/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1053897615295856640/c:line/m:interactions.svg)

- X Week XXXXXX +300%
- X Month XXXXXX +87%
- X Months XXXXXX +447%
- X Year XXXXXX +503,095%

### Mentions: XX [#](/creator/twitter::1053897615295856640/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1053897615295856640/c:line/m:posts_active.svg)

- X Week XX +263%
- X Month XX +91%
- X Months XX +986%
- X Year XX +8,200%

### Followers: XXXXX [#](/creator/twitter::1053897615295856640/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1053897615295856640/c:line/m:followers.svg)

- X Week XXXXX +2.10%
- X Month XXXXX +6.50%
- X Months XXXXX +21%
- X Year XXXXX +43%

### CreatorRank: XXXXXXX [#](/creator/twitter::1053897615295856640/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1053897615295856640/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1053897615295856640/influence)
---

**Social category influence**
[nba](/list/nba)  #1048 [travel destinations](/list/travel-destinations)  XXXX% [currencies](/list/currencies)  XXXX% [cryptocurrencies](/list/cryptocurrencies)  XXXX%

**Social topic influence**
[promising](/topic/promising) #81, [matterhorn](/topic/matterhorn) 6.67%, [combo](/topic/combo) 6.67%, [cest](/topic/cest) 3.33%, [sts](/topic/sts) 3.33%, [os](/topic/os) 3.33%, [signals](/topic/signals) 3.33%, [events](/topic/events) 3.33%, [accuracy](/topic/accuracy) 3.33%, [linked](/topic/linked) XXXX%

**Top accounts mentioned or mentioned by**
[@oncoalert](/creator/undefined) [@myesmo](/creator/undefined) [@grupottd](/creator/undefined) [@koheishitara](/creator/undefined) [@drdelolmombel](/creator/undefined)
### Top Social Posts [#](/creator/twitter::1053897615295856640/posts)
---
Top posts by engagements in the last XX hours

"📣 Dont miss #ESMO25 Proffered Session Upper GI (14:00 CEST) X MATTERHORN: Durva+FLOT (resectable GC/GEJ) X SKYSCRAPER-07: Tira+Atezo (post-dCRT ESCC) X LEAP-014: Len+Pembro+CT (1L mESCC) X INTEGRATE IIb: Rego+Nivo (refractory GC/GEJ) X KN026: Anbenitamab+CT (HER2+) @myESMO"  
[X Link](https://x.com/DraMartinezLago/status/1979109743902834908) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-17T08:58Z 2417 followers, 2297 engagements


"🔹 #ESMO25 #Sarcoma Phase III MANEUVER: pimicotinib in TGCT (n=63) 🧩 ORR (BIRC RECIST v1.1): XXXX% (95% CI 63.886.0) 🧩 ORR (TVS): XXXX% (95% CI 62.184.7) Median DOR NR 💪 Sustained tumor response better function pain relief ⚕ Well tolerated few discontinuations"  
[X Link](https://x.com/DraMartinezLago/status/1979197490923450821) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-17T14:47Z 2417 followers, XXX engagements


"🚨 #ESMO25 #LowerGI 📍 Dont miss Proffered Paper 1: Lower GI 🕓 14:4516:15 💥 Highlights: PEGASUS ctDNA-guided therapy stage IIIII CRC FOxTROT & NICHE-2 neoadjuvant in dMMR colon cancer CITRIC & PARERE ctDNA-driven anti-EGFR in mCRC @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1979479542839321004) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-18T09:27Z 2426 followers, XXX engagements


"#ESMO25 #UpperGI Phase III MATTERHORN: Durvalumab + FLOT vs Placebo + FLOT in resectable G/GEJ cancer (n=948). 🔹 HR XXXX (95% CI 0.630.96); p=0.021 🔹 24-mo OS XXXX% vs XXXX% 36-mo XXXX% vs XXXX% ➡ New SOC for localized G/GEJ cancer"  
[X Link](https://x.com/DraMartinezLago/status/1979159124538523855) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-17T12:14Z 2428 followers, XXX engagements


"#ESMO25 #NETs ASPEN: AS vs surgery in X cm NF-PanNETs 🧩 XX% on AS 🧩 5-yr growth XXXX% Liver mets XXX% ⚕ XX% severe post-op issues no deaths 💡 AS and surgery OS similar AS safe for most X cm NF-PanNETs ✅ @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1979464455541899364) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-18T08:27Z 2428 followers, XXX engagements


"#ESMO25 #NETs LITESPARK-015 Belzutifan (HIF-2 inhibitor) in advanced PPGL 🧩 ORR XX% DCR XX% mPFS XX mo mOS NR 🩸 XX% in antihypertensive medication X mo ⚕ Grade XX TRAEs XX% (mostly anemia hypoxia) no grade X 💡 Durable responses with manageable safety ✅ @OncoAlert @myESMO"  
[X Link](https://x.com/DraMartinezLago/status/1979467628604182583) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-18T08:40Z 2429 followers, 1151 engagements


"📢 #ESMO25 #NETs Dabra + trame (Ph III) in RAI-refractory BRAF V600Emt DTC 🧩 mPFS XXXX vs XXX mo HR 0.38; p0.001 🧩 ORR XX% vs X% ⚕ Gr X AEs: pyrexia (6%) anemia (5%) pneumonia (6%) ✅ Benefit across subgroups 💡 New tx for BRAF V600E-mutant DTC @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1979471097520370054) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-18T08:54Z 2429 followers, 1175 engagements


"📢 #ESMO25 #NETs COMPETE trial: Lu-edotreotide vs everolimus in G12 GEP-NETs 🧩 mPFS XXXX vs XXXX mo HR XXXX (95% CI 0.480.95); p=0.022 🧩 ORR XX% vs X% (p0.0001) ⚕ Drug-related discontinuations: X% vs XX% 💡 Lu-edotreotide outperforms everolimus safer ✅ @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1979477047199011166) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-18T09:17Z 2429 followers, 1770 engagements


"📢 #ESMO25 #NETs XT-XTR008-3-01 Lu (XTR008) vs hd Octreotide LAR in G12 GEP-NETs 🧩 mPFS XXXX vs XXX mo HR XXXX (p 0.0001) 🧩 ORR XX% vs X% DCR XX% vs XX% ⚕ Manageable safety MDS X% no AML/deaths 💡 XTR008 significantly improved PFS ORR & QoL vs LAR ✅ @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1979479235925356670) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-18T09:26Z 2428 followers, XXX engagements


"🚨 Dont miss #ESMO25 #LowerGI 📍 Mini Oral Session 🕓 14:4516:15 X cfDNA blood test for early CRC detection X INTERCEPT ctDNA clearance & outcomes X DESTINY-CRC02 T-DXd in HER2 mCRC (final) X OPTIPRIME Stop-and-go PAN + FOLFOX X TriComB FTD/TPI + Cape + Bev upfront X DeFianCe DKN-01 + Bev + chemo (MSS CRC) X ABBV-400 + Bev (phase I combo) @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1979844012837077454) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-19T09:36Z 2426 followers, XXX engagements


"🧬 #ESMO25 #Sarcoma Legubicin vs DOXO in STS (Phase II/III) 📊 mPFS XXXX vs XXX mo HR XXXX (p0.0001) OS HR 0.49; ORR XXXX% vs XXXX% 💗 G3 cardiotoxicity XXX% vs XXXX% G3 hematologic XXXX% vs XXXX% 💥 Potential new 1L standard for advanced STS @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1979921346113966440) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-19T14:43Z 2429 followers, 1109 engagements


"🚨 Dont miss #ESMO25 #NETs Mini Oral Session 🕣 08:3010:00 X ZG006 (Phase II): Trispecific T-cell engager (DLL3/DLL3/CD3) in refractory NEC early efficacy. X ZG005 + EP (Phase II): 1L NEC combo showing enhanced activity vs chemo alone. X Triapine + Lu-DOTATATE (Phase I): Synergistic DNA damage + PRRT in well-diff GEP-NETs. X PbVMT--NET & ALPHAMEDIX-02: Targeted alpha therapies with durable responses in SSTR2 NETs. X NUTRIGETNE (GETNE-S2109): Predictive model for malnutrition/sarcopenia in GEP-NENs. X Belzutifan (LITESPARK-015): Promising activity in advanced panNETs. X Organoid models:"  
[X Link](https://x.com/DraMartinezLago/status/1979938947896586361) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-19T15:53Z 2429 followers, XXX engagements


"#ESMO25 #NETs 🧬 Alveltamig (ZG006 Ph II) Trispecific T-cell engager (DLL3/CD3) in refractory NEC 📊 ORR XXXX% (10 mg) vs XXXX% (30 mg) DCR XXXX% vs XXXX% 🎯 DLL3 50%: ORR XXXX% DCR XXXX% 💊 Gr X TRAEs XX% (mostly CRS G1-2) 💥 Supports further dev in DLL3-high NEC @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1980161714680140026) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T06:38Z 2429 followers, XXX engagements


"#ESMO25 #NETs 🧬 Phase I/II ZG005 (anti-PD-1/TIGIT) + EP in untreated NEC 📊 ORR: XX% (20 mg/kg) vs XX% (10 mg/kg) vs XX% (EP alone) DCR: XXX% 💊 Gr3 TRAEs: XX% (10 mg/kg) XX% (20 mg/kg) XX% (EP); mostly hematologic ✅ Promising efficacy manageable safety. @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1980164427128127840) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T06:49Z 2429 followers, 1078 engagements


"#ESMO25 #NETs 🧬 Phase I NCI trial: Triapine + Lu-DOTATATE in progressive GEP-NETs 📊 ORR XX% (6/28 PR) XX% SD Median PFS NR 💊 AEs: anemia (87%) lymphopenia (87%) thrombocytopenia (71%) mostly transient ✅ DL2 (150 mg) RP2D Phase II (ETCTN 10558)"  
[X Link](https://x.com/DraMartinezLago/status/1980168940367278428) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T07:07Z 2429 followers, XXX engagements


"#ESMO25 #NETs 🧬 Phase I NCI trial: Triapine + Lu-DOTATATE in progressive GEP-NETs 📊 ORR XX% (6/28 PR) XX% SD Median PFS NR 💊 AEs: anemia (87%) lymphopenia (87%) thrombocytopenia (71%) mostly transient ✅ DL2 (150 mg) RP2D Phase II (ETCTN 10558) @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1980169053898420265) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T07:07Z 2429 followers, XXX engagements


"#ESMO25 #NETs PbVMT--NET (Phase I/IIa NCT05636618) 📈 PR in 4/7 pts (Cohort X XXX MBq) 💊 No G4 AEs no renal toxicity no dysphagia ✅ Well-tolerated next-gen TAT with early efficacy signals 🔬 Further clinical development warranted @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1980172612602134736) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T07:21Z 2429 followers, 1570 engagements


"#ESMO25 #NETs Phase II ALPHAMEDIX-02 Pb-DOTAMTATE in RLT-nave adv GEP-NETs 📊 ORR XX% DCR XX% DoR 24m (72%) 36m PFS XX% OS XX% 💊 Mostly G12 AEs; rare dysphagia/renal events; no MDS/AML ✅ Durable efficacy + safe profile confirm -therapy as promising NET option @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1980173327663526344) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T07:24Z 2429 followers, XXX engagements


"#ESMO25 #NETs @drdelolmo_mbel presents NUTRIGETNE (GETNE-S2109) study 💪 📊 Cross-sectional study in adv. GEP-NENs 🔎 LASSO models for malnutrition (GLIM) & sarcopenia (EWGSOP) 🎯 Accuracy: XXXX% (malnutrition) XXXX% (sarcopenia) ✅ NUTRIGETNE Score: accessible rapid cost-effective nutritional risk screening tool @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1980179934346682609) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T07:51Z 2429 followers, 1093 engagements


"#ESMO25 #NETs Belzutifan (HIF-2 inhibitor LITESPARK-015 Phase II) in advanced panNETs 📊 ORR XX% DCR XX% mPFS XXX mo 💊 Anemia (73%) most frequent AE Gr3 XX% ✅ Modest activity with manageable safety profile; further investigation warranted @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1980181548835201063) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T07:57Z 2429 followers, 1520 engagements


"#ESMO25 #UpperGI IMMUNOBIL (Phase II) Durvalumab + tremelimumab (STRIDE) in pretreated BTC 📊 6-mo OS XX% mOS XXX mo ORR XX% DCR XX% 💊 Gr3 TRAE XX% PD-L1 X linked to better OS (12.8 vs XXX mo) ⚠ Primary endpoint narrowly missed but activity seen in subsets @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1980279555848859849) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T14:26Z 2429 followers, XXX engagements


"#ESMO25 #UpperGI VIRAGE (Phase IIb) VCN-01 + gem/nab-paclitaxel vs GA alone in mPDAC 📈 mOS XXXX vs XXX mo (HR 0.57; p=0.055) mPFS XXX vs XXX mo (p=0.011) 💊 Well tolerated; transient flu-like & liver AEs ✅ Improved OS PFS & DoR; meets primary endpoint @myESMO @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1980281229795885080) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T14:33Z 2429 followers, XXX engagements


"#ESMO25 #UpperGI Temab-A (ABBV-400 Phase I) c-Mettargeting ADC (Temab-A) in advanced PDAC 📊 ORR XX% overall XX% post 1L gemnab-paclitaxel mPFS XXX mo 💊 G3 AEs: anemia XX% neutropenia XX% ILD XXX% ✅ Promising early efficacy @OncoAlert"  
[X Link](https://x.com/DraMartinezLago/status/1980281798094377357) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T14:35Z 2429 followers, XXX engagements